SCHEMBL2146772

SCHEMBL2146772

Cc1noc(C)c1-c1c(C=NO)c2ccccc2n1-c1cc(F)c(O)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 10/20 0.36
CYP2C19 P33261 7/20 0.36
ALOX15 P16050 6/20 0.36
HSD17B10 Q99714 6/20 0.36
ALDH1A1 P00352 5/20 0.36
USP2 O75604 5/20 0.36
LMNA P02545 5/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
APEX1 P27695 1/20 0.36
TSHR P16473 4/20 0.35
MAPK1 P28482 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CYP3A4 P08684 9/20 0.35
CLK4 Q9HAZ1 6/20 0.35
ERN1 O75460 3/20 0.35
CYP2C9 P11712 2/20 0.35
BRD4 O60885 3/20 0.33
NPY2R P49146 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2146768 1.00 CYP1A2 (0.36) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2146365 0.90 ALOX15 (0.38) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2146361 0.90 ALOX15 (0.38) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2285279 0.89 ERN1 (0.43) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2286335 0.87 CYP1A2 (0.36) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2146496 0.87 CYP1A2 (0.36) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2159526 0.87 CYP1A2 (0.37) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2159532 0.87 CYP1A2 (0.37) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2147668 0.85 ERN1 (0.40) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1
SCHEMBL2147661 0.85 ERN1 (0.40) CYP1A2CYP2C19ALOX15HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-08-18 US claimed
EP-2346824-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-07-27 EP claimed
WO-2010031852-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2010-03-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201555-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, ESRRA, GPER1 CYP1A2 1232/4885CYP2C19 1258/4885ALOX15 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.